Pazufloxacin  (Synonyms: T3761)

Pazufloxacin is an orally active fluoroquinolone antimicrobial agent. Pazufloxacin inhibits DNA gyrase with IC₅₀ values of 0.88 μg/mL (E. coli) and 1.9 μg/mL (P. aeruginosa). Pazufloxacin exhibits broad-spectrum antimicrobial activity, with MIC₉₀ values ranging from 0.025 to 100 μg/mL against Gram-positive and Gram-negative bacteria, non-fermenting bacteria, Legionella spp., and anaerobic bacteria. Pazufloxacin is indicated for research on systemic infections, lung infections, urinary tract infections, and Legionella pneumonia^{[1][2][3][4][5]}.

Pazufloxacin shows broad-spectrum antibacterial activity with MIC₉₀s ranging from 0.025 to 100 μg/mL against gram-positive bacteria, gram-negative bacteria, non-fermenters, Legionella spp., and anaerobes^[1].
Pazufloxacin inhibits DNA gyrase with IC₅₀s of 0.88 μg/mL (E. coli) and 1.9 μg/mL (P. aeruginosa)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pazufloxacin (25 mg/kg; p.o.) shows good efficacy in mice with pulmonary infections, achieving 94% survival and eradication rates against Pseudomonas aeruginosa, which is greater than that of Ofloxacin (HY-B0125) and Norfloxacin (HY-B0132)^[1].
Pazufloxacin (5 mg/kg/day; i.p.; twice a day; 7 days) in combination with Sivelestat (HY-17443) reduces bacterial counts and inflammatory cells in the early phase of Legionella pneumonia in A/J mice, but does not significantly improve survival compared to monotherapy^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

318.30

C₁₆H₁₅FN₂O₄

127045-41-4

O=C(C(C1=O)=CN2[C@@H](C)COC3=C(C4(N)CC4)C(F)=CC1=C23)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fukuoka, Y., et al., In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother, 1993. 37(3): p. 384-92.  [Content Brief]

  [2]. Muratani, T., M. Inoue, and S. Mitsuhashi, In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother, 1992. 36(10): p. 2293-303.  [Content Brief]

  [3]. Takei M, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.  [Content Brief]

  [4]. Sousa J, et al. First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jul 1;930:104-11.  [Content Brief]

  [5]. Morinaga Y, et al. In vivo efficacy of sivelestat in combination with pazufloxacin against Legionella pneumonia. Exp Lung Res. 2010 Oct;36(8):484-90.  [Content Brief]